Editas Medicine Inc (EDIT) — Titan Protect Analysis

EDIT

Editas Medicine Inc

Healthcare · ·

$2.71

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$424M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-2.95

Based on estimated future earnings — lower means cheaper

Rev Growth

-39.2%

Year-over-year revenue change

Profit Margin

-281.6%

How much profit the company keeps from each dollar of revenue

ROE

-326.1%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$5.00

+85% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 9 analysts covering this stock

About Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalasse

https://www.editasmedicine.com

Country: United States Employees: 87 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

0.235

Positive but modest risk-adjusted returns

Kelly Fraction

-0.0006

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.323

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-27.1%

Historical annualised return based on price data

Max Drawdown

-83.8%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

2.14

Significantly more volatile than the market

52W High

$4.54

40% below the year high

52W Low

$1.66

63% above the year low

Avg Volume

2,064,717

Average daily shares traded — higher means easier to buy and sell

Short Ratio

7.4

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-1.14

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

392.40

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

-109.2%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-883.2%

Profit from core operations before interest and tax

Free Cash Flow

$-73,816,000

Negative — the business is spending more than it generates

Revenue (TTM)

$39M

Total revenue over the last 12 months

Net Income

$-108,954,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$15.00

Target Median

$5.00

Target Low

$1.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go